Luz Martin-Carbonero

Summary

Publications

  1. doi request reprint New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:379-82. 2010
  2. ncbi request reprint Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B?
    Luz Martin-Carbonero
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 28:1262-4. 2012
  3. doi request reprint Hepatitis B virus and HIV infection
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Semin Liver Dis 32:114-9. 2012
  4. doi request reprint Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection
    L Martin-Carbonero
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 16:790-5. 2009
  5. doi request reprint Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin
    L Martin-Carbonero
    Dept of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 47:410-7. 2008
  6. doi request reprint Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4
    L Martin-Carbonero
    Department of InfectiousDiseases, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 15:710-5. 2008
  7. doi request reprint Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis
    L Martin-Carbonero
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 18:542-8. 2011
  8. doi request reprint Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 25:73-9. 2011
  9. ncbi request reprint Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:163-71. 2006
  10. ncbi request reprint Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:657-62. 2005

Detail Information

Publications74

  1. doi request reprint New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:379-82. 2010
    ..It may allow the early recognition of HBV viraemic individuals who may benefit from either initiating or switching antiviral therapy. In any situation, the use of anti-HBV therapies more potent than lamivudine alone is warranted...
  2. ncbi request reprint Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B?
    Luz Martin-Carbonero
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 28:1262-4. 2012
    ..2% vs. 44.9%; p=0.3. Thus, the interleukin-28B (IL-28B) genotype does not seem to have a role in the development of chronic hepatitis B among HIV-infected patients...
  3. doi request reprint Hepatitis B virus and HIV infection
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Semin Liver Dis 32:114-9. 2012
    ....
  4. doi request reprint Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection
    L Martin-Carbonero
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 16:790-5. 2009
    ..5% of HCV-HIV co-infected patients with PNALT. Some degree of liver fibrosis that justifies treatment is seen in 15% of the HCV-monoinfected but doubles to nearly 30% in HIV-HCV co-infected patients with PNALT...
  5. doi request reprint Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin
    L Martin-Carbonero
    Dept of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 47:410-7. 2008
    ..However, this tumor still represents the most common cancer in this population...
  6. doi request reprint Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4
    L Martin-Carbonero
    Department of InfectiousDiseases, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 15:710-5. 2008
    ..Therefore, these patients should be considered as difficult to treat population. Baseline serum HCV-RNA and EVR are the best predictors of SVR in HCV-4 / HIV-coinfected patients...
  7. doi request reprint Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis
    L Martin-Carbonero
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 18:542-8. 2011
    ..Therefore, treatment must be encouraged in all compensated cirrhotic patients, although closer monitoring and management of side effects, mainly thrombocytopenia, may be warranted...
  8. doi request reprint Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 25:73-9. 2011
    ..Nucleos(t)ide analogues with activity against both HBV and HIV are widely used in coinfected patients, but its long-term effect on liver disease is unknown...
  9. ncbi request reprint Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:163-71. 2006
    ..Regimens based on ritonavir-boosted protease inhibitors (PI/r) are often used as rescue interventions. It is unclear whether significant differences exist between distinct PI/r...
  10. ncbi request reprint Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:657-62. 2005
    ..The use of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is currently the recommended treatment for chronic hepatitis C virus (HCV) infection. Coinfection with HIV is a negative predictor of response, for reasons not well understood...
  11. ncbi request reprint Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006
    ..The relatively low efficacy of current anti-HCV medications and their low tolerability clearly indicated the need for new drugs with more potent and direct antiviral activity against HCV...
  12. ncbi request reprint Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  13. ncbi request reprint Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:304-9. 2002
    ..It has shown greater potency than the former PIs in phase II/III trials, either in naive or in PI-experienced patients being naive for nonnucleoside reverse transcriptase inhibitors (NNRTIs)...
  14. ncbi request reprint Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:842-8. 2006
    ..Thus, HBV/HIV-coinfected patients might benefit from an earlier introduction of HAART...
  15. ncbi request reprint Predictors of virological response to atazanavir in protease inhibitor-experienced patients
    Ana Barrios
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 5:201-5. 2004
    ..Atazanavir (ATV) is the latest approved HIV protease inhibitor (PI). Even though it is very convenient (only two capsules once a day), concerns have risen about its potency...
  16. doi request reprint Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J Acquir Immune Defic Syndr 53:364-8. 2010
    ....
  17. ncbi request reprint Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 9:505-9. 2004
    ..Therefore, extending therapy (for 12 months in HCV genotypes 2/3 and perhaps for 18 months in HCV genotypes 1/4) might be warranted in HIV/HCV-coinfected patients showing EVR...
  18. ncbi request reprint Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
    Luz Martin-Carbonero
    Hospital Carlos III, CIBERehd, Madrid, Spain
    AIDS 22:15-21. 2008
    ..It is unclear whether this applies to HIV/HCV-co-infected patients...
  19. ncbi request reprint Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain
    J Infect Dis 196:670-6. 2007
    ..It is unknown whether sustained HCV clearance after interferon (IFN)-based therapy might reduce this complication...
  20. ncbi request reprint Severe liver disease associated with prolonged exposure to antiretroviral drugs
    Ivana Maida
    Department of Infectious Diseases, Hospital Carlos III, Madrid Spain
    J Acquir Immune Defic Syndr 42:177-82. 2006
    ..However, the etiology of liver disease still remains unknown for a small subset of individuals...
  21. ncbi request reprint Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:1231-5. 2006
    ..The presence of TAMs precluded the selection of K65R in patients treated with TDF. Resistance pathways for TDF and thymidine analogues seem to be divergent and could be the basis to explore a synergism between these drugs...
  22. ncbi request reprint Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 61:200-5. 2008
    ..If proved, this strategy could be particularly attractive for the subset of patients with greater cardiovascular risk...
  23. ncbi request reprint Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos II, Madrid, Spain
    Antivir Ther 9:987-92. 2004
    ..However, the occurrence of liver complications (including hepatocellular carcinoma) and/or HCV relapses in coinfected patients when followed for long periods of time after HCV therapy is not well known...
  24. ncbi request reprint SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:186-94. 2002
    ..A randomized, open-label, pilot study was undertaken to explore the antiviral activity and tolerability of two nonnucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (NVP) and efavirenz (EFV)...
  25. ncbi request reprint Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008
    ..Differences between PEG-IFN-alpha molecules could be more pronounced in HIV-coinfected individuals, in whom response to HCV treatment is impaired...
  26. ncbi request reprint Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Med Virol 76:1-6. 2005
    ..Thus, keeping on treatment HIV-infected individuals failing virologically and harboring drug-resistant viruses may ameliorate their immunological deterioration until new drugs became available...
  27. ncbi request reprint Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 21:583-8. 2007
    ..Information on the impact of therapy with pegylated interferon (pegIFN) plus ribavirin on mtDNA is scarce and conflicting results have been reported...
  28. ncbi request reprint Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors
    Pablo Barreiro
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    Int J Antimicrob Agents 20:438-43. 2002
    ..The efficacy of rit-boosted PI combinations is greatly influenced by the extent of baseline PI resistance. Differences, not only in potency, but mainly in tolerance may favour the selection of one dual PI combination over others...
  29. doi request reprint Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients
    Jose Medrano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 49:1397-401. 2009
    ..However, episodes of HCV relapse occurred before week 12 in most cases, regardless of HIV status...
  30. ncbi request reprint [Hepatitis B in patients with HIV infection]
    Pablo Barreiro
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:71-9. 2008
    ..Patients with cirrhosis should undergo ultrasonography and alphafetoprotein determination every 6 months for the early detection of hepatocellular carcinoma...
  31. ncbi request reprint Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients
    Ana Lucía Rendon
    Pharmacy Service, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 39:401-5. 2005
    ..Therefore, early therapeutic drug monitoring might help to tailor RBV dosages, improving the efficacy and safety of anti-HCV treatment...
  32. ncbi request reprint Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 42:1032-9. 2006
    ..The reasons for this faster liver disease progression are unclear, although higher plasma HCV RNA levels and distinct HCV genotype distribution in this population, compared with in HCV-monoinfected subjects, could play a role...
  33. ncbi request reprint Update on the treatment of chronic hepatitis C in HIV-infected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 9:99-113. 2007
    ..g. tenofovir, lamivudine, or emtricitabine). Didanosine should never be coadministered with ribavirin due to potential life-threatening complications...
  34. ncbi request reprint New paradigms in the management of HIV and hepatitis C virus coinfection
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Curr Opin Infect Dis 18:550-60. 2005
    ..The bidirectional interferences between hepatitis C virus and HIV have clinical consequences and complicate the management of coinfected individuals...
  35. ncbi request reprint Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
    Mayte Pérez-Olmeda
    Service of Infectious Diseases and bHepatology Unit, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 17:1023-8. 2003
    ..Treatment of hepatitis C virus (HCV) has become a major challenge in HIV-infected individuals. No data exist on the efficacy and tolerability of pegylated IFN (peg-IFN) plus ribavirin in HIV-co-infected patients...
  36. ncbi request reprint Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:167-70. 2005
    ..HCV genotype 4 is spreading among European intravenous drug users, who are frequently coinfected with HIV. Information about treatment response in this subset of patients is scarce and conflicting results have been reported...
  37. ncbi request reprint Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 11:869-77. 2006
    ..Unfortunately, hepatitis C virus (HCV) therapy provides sustained virological response (SVR) to only 40% of coinfected patients. Little is known about the regression of hepatic fibrosis in treated patients...
  38. ncbi request reprint Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients
    Belen Ramos
    Service of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Acquir Immune Defic Syndr 44:557-61. 2007
    ..Information available on the prevalence and distribution of distinct HBV variants in HIV-positive patients is scarce...
  39. ncbi request reprint Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients
    Maria José Nuñez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:825-9. 2006
    ..All subjects with ARV-related toxicities had a favorable outcome, except one with prior HCVrelated end-stage liver disease, who died after experiencing hepatic decompensation following initiation of a protease inhibitor-based regimen...
  40. ncbi request reprint Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 195:973-9. 2007
    ..Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency...
  41. doi request reprint Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 17:571-5. 2012
    ..Herein, we report the current profile of HIV-HCV-coinfected patients at our institution in an attempt to predict the effect of DAAs...
  42. doi request reprint Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy
    Paula Tuma
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 15:881-6. 2010
    ..Herein, we examine the incidence of cirrhosis, using TE assessment, in HIV-infected individuals with chronic hepatitis B or C receiving highly active antiretroviral therapy (HAART)...
  43. ncbi request reprint Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, 28029, Spain
    J Infect Dis 195:1181-3. 2007
    ..This information has important pathogenic implications and may influence therapeutic decisions...
  44. ncbi request reprint Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 19:569-75. 2005
    ..The popularity of this combination, however, has been questioned due to concerns about pharmacokinetic interactions and increased risk of pancreatitis and hyperglycemia. Less information is available about other possible side effects...
  45. ncbi request reprint Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS 21:41-6. 2007
    ..Polymorphisms at the uridin-glucoronosyl-transferase 1A1 (UGT1A1) and multidrug resistance 1 (MDR1) genes may influence, respectively, bilirubin and ATV plasma concentrations...
  46. ncbi request reprint Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution
    Luz Martin-Carbonero
    Service of Infectious Diseases Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 16:1423-5. 2002
    ..Underlying chronic hepatitis may thus increase the risk of liver toxicity by other mechanisms...
  47. doi request reprint [Human immunodeficiency virus infection and viral hepatitis]
    Vicente Soriano
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 29:691-701. 2011
    ..However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population...
  48. ncbi request reprint Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 60:885-8. 2007
    ..To estimate to what extent darunavir might be effective in patients failing distinct protease inhibitors (PIs), the genotypic resistance scores recently reported for the drug were examined in a large clinical HIV-1 drug resistance database...
  49. ncbi request reprint Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 30:65-8. 2002
    ..To assess the role of different hepatitis C virus (HCV) genotypes in the development of transaminase elevation after treatment with highly active antiretroviral therapy (HAART)...
  50. doi request reprint Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
    Pablo Labarga
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS 23:689-96. 2009
    ..Kidney abnormalities are the main concern using the drug. As glomerular function is infrequently affected in patients treated with TDF, herein, we report the results of an extensive examination of tubular function...
  51. ncbi request reprint Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations
    Luisa Valer
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 18:2094-6. 2004
    ..3%), of whom 10 had never been exposed to tenofovir. The rate of K65R increased from 0.6% in 1999 to 11.5% in 2004. The recognition of K65R correlated negatively with the presence of thymidine analogue mutations but positively with Q151M...
  52. ncbi request reprint Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
    Vincent Soriano
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:469-76. 2007
    ..Chronic hepatitis C therapy in HIV patients is often penalized by more frequent premature treatment discontinuations. It is unclear what the relative contribution of more adverse events and/or early virological failures are...
  53. pmc Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients
    Ana Barrios
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    J Clin Microbiol 41:4421-3. 2003
    ..Only five (3.7%) patients discontinued TDF use due to adverse events. In the multivariate analysis, the presence of M41L and/or L210W at baseline was the only viral determinant of a lower response to TDF...
  54. doi request reprint Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome
    Pilar Garcia-Gasco
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 61:699-704. 2008
    ..The rate, predictors and outcome following episodes of low-level viral rebound (LLVR) in HIV patients on highly active antiretroviral therapy (HAART) are unknown...
  55. ncbi request reprint Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine
    Luz Martin-Carbonero
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 4:115-20. 2003
    ..To compare the incidence and define the risk factors associated with liver toxicity in patients beginning treatment with nevirapine (NVP) and efavirenz (EFZ)...
  56. ncbi request reprint Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos Ill, Instituto de Salud Carlos Ill, Madrid, Spain
    AIDS 16:1959-61. 2002
  57. ncbi request reprint Gynecomastia in HIV-infected patients receiving antiretroviral therapy
    Teresa Garcia-Benayas
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, 28035 Madrid, Spain
    AIDS Res Hum Retroviruses 19:739-41. 2003
    ..Although initially unilateral, more than half of cases progressed to bilateral gynecomastia. Spontaneous resolution occurred in most subjects with 12 months without modifying therapy...
  58. ncbi request reprint Complications in treating chronic hepatitis B in patients with HIV
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Expert Opin Pharmacother 6:2831-42. 2005
    ..Although response to IFN-alpha is poorer in HBV/HIV-coinfected patients compared with HBV-monoinfected individuals, the more potent pegylated forms of IFN-alpha have brought new hopes...
  59. doi request reprint Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy
    Pablo Barreiro
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Infect Dis 203:1629-36. 2011
    ....
  60. ncbi request reprint Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:246-50. 2006
    ..The extent and predictors of liver fibrosis were examined in a HIV/HBVcoinfected cohort with extensive exposure to anti-HBV active HAART...
  61. ncbi request reprint Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens
    Luisa Valer
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Patient Care STDS 18:1-6. 2004
    ..In summary, HIV genotyping but not drug levels might be helpful to predict which patients would benefit from a rescue intervention based on APV/RTV 600/100 twice daily...
  62. ncbi request reprint Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study
    Luz Martin-Carbonero
    Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 38:128-33. 2004
    ..The rate of complications due to end-stage liver disease will inevitably increase in this population, for whom anti-HCV therapy should be considered a priority...
  63. doi request reprint Directly acting antivirals against hepatitis C virus
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 66:1673-86. 2011
    ..The complexity of HCV therapeutics has reached a point that presumably will lead to the birth of a new specialist, the HCV doctor...
  64. doi request reprint Survival of HIV-infected patients with compensated liver cirrhosis
    Paula Tuma
    Department of Infectious Diseases, Hospital Carlos III, Spain
    AIDS 24:745-53. 2010
    ....
  65. ncbi request reprint Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals
    Oscar Gallego
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Virol Methods 121:115-8. 2004
    ..The inclusion of additional sequences in the VircoNET database, mainly those derived from heavily treatment-experienced patients and/or from patients failing the most recently approved drugs might improve its performance...
  66. ncbi request reprint Emerging drugs for hepatitis C
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Emerg Drugs 13:1-19. 2008
    ....
  67. ncbi request reprint Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome
    Ivana Maida
    Department of Infectious Diseases, Hospital Carlos III, Madrid Spain
    Antivir Ther 13:103-7. 2008
    ..Herein, we examine the clinical outcome following ddl removal...
  68. doi request reprint Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up
    Maribel Quezada
    Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain
    AIDS 26:1387-92. 2012
    ..Transthoracic echocardiography (TTE) is a noninvasive tool validated for PAH screening. The aim of our study was to establish the prevalence and factors associated with PAH in HIV-infected patients...
  69. ncbi request reprint Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years
    Veronica Briz
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 61:405-10. 2008
    ..Viral tropism plays a major role in HIV pathogenesis and may influence the activity of entry inhibitors. The impact of antiretroviral therapy use on the dynamics of viral tropism over time is still poorly understood...
  70. doi request reprint Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid
    Carla Núñez-Fernández
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:383-5. 2009
    ..Hepatic complications are currently still responsible for 8.7% of all hospital admissions and one-third of in-hospital deaths, with hepatitis C virus infection by far the leading etiologic agent...
  71. ncbi request reprint Management and therapy of chronic hepatitis C in HIV
    Vincent Soriano
    aDepartment of Infectious Diseases, Spain bHepatology Unit, CIBERehd, Hospital Carlos III, Madrid, Spain
    Curr Opin HIV AIDS 2:482-8. 2007
    ..Chronic hepatitis C is currently one of the leading causes of hospitalization and death in HIV+ persons. Treatment is particularly challenging in coinfected patients due to lower efficacy and more side effects...
  72. pmc Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy
    Eduardo Seclen
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 204:139-44. 2011
    ..There is scarce information about the influence of viral tropism on treatment outcomes...
  73. doi request reprint [Malignancies in HIV infected patients: study of 139 cases]
    Germán Ramírez-Olivencia
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Med Clin (Barc) 133:729-35. 2009
    ..A total of 139 HIV-infected patients were identified who had at least one malignancy. Statistical analysis was performed using SPSS 15.0 package...
  74. ncbi request reprint Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality
    Paz Sobrino-Vegas
    Red de Investigación en SIDA, Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    Curr HIV Res 7:224-30. 2009
    ..Although we did not find differences in virological and immunological responses to HAART, we did observe higher mortality in people with DHD. Increased efforts to early diagnose HIV infection are urgently needed...